Pricing Debate
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.

Sanofi Joins Peers, Will Make Lantus Available At $35 For All US Patients
Sanofi is the last of three big insulin makers to offer its top-selling insulin at the same out-of-pocket cost regardless of patients’ insurance coverage, but calls for other health care players to make concessions as well.

IRA Drug Pricing Implications Impact Pharma Views On Deal Terms, Valuations
Pharma business development executives and venture capital investors shared their thoughts on the Inflation Reduction Act at Biocom’s Global Life Science Partnering and Investor Conference in San Diego.

ICER’s Leqembi Assessment Inches Higher, Still Sees Eisai Price As Too High
The drug pricing watchdog said in its revised report that Alzheimer’s therapy Leqembi (lecanemab) meets cost-effectiveness thresholds at $8,900-$21,500, below Eisai/Biogen’s $26,500 list price.

For Some Biotechs, IRA Remains Intangible – For Now
Some biotech leaders say IRA policies don’t feel consequential yet, though small companies could face impacts from R&D and M&A decision making at big pharmas.

Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: Merck & Co. tells Scrip oncology will remain a key priority; J&J is responsibly cautious on growth; Takeda pays big for HutchMed drug; industry looks at likely US IRA impact; and lecanemab misses out on EU fast-track treatment.

Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: the best of J.P. Morgan; Novartis on its US-first commercial plan; Chugai CEO talks to Scrip on the Roche alliance and more; Scrip Asks what this year holds for pricing and reimbursement; and the global outlook for biopharma funding.

Industry Looks At IRA Drawbacks And Silver Linings
Industry leaders are concerned about the outlook for small molecule drugs in particular, but execs at the J.P. Morgan Healthcare Conference were also optimistic there could be chances to shape the implementation of certain policies.

Stock Watch: Spanners In The Works For Q4 Results
While the implications of the US Inflation Reduction Act are the focus of the sector’s concern this year, another regulatory development will impact earnings sooner.

Scrip Asks… What Does 2023 Hold For Biopharma? Part 4: Pricing And Reimbursement
Biopharma executives see value-based pricing as an increasingly important topic for the sector in 2023, while the US Inflation Reduction Act will have a major impact on portfolio strategies.

Stock Watch: J.P. Morgan Conference, Big Splash News And Stock Prices
Timing big M&A transactions to coincide with the biggest investor conference of the year is difficult. But getting it right can boost stocks across the sector.

Scrip Asks…What Does 2023 Hold For Biopharma? Part 3: Global Headwinds
Headwinds of political instability, violent conflict, inflation and recession accompany us into 2023. Scrip surveyed industry leaders on the impacts for biopharma.

COVID-19 Windfalls Carry Pharma Into Stormy Times: Key Takeaways From Scrip 100 And Outlook 2023
The past couple of years have generated important growth for the pharma industry thanks to its drugs and vaccines for COVID-19. But with the IRA, high inflation, rising interest rates and chilly public markets, biopharma faces challenges this year. Here, we summarize key messages from In Vivo’s Outlook 2023.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.